10-Q/A: Integer Holdings Updates Sales Outlook, Cites New Product Adoption Challenges

Integer Holdings Corporation filed an amended quarterly report to provide additional context on its sales outlook, noting lower than anticipated demand for certain emerging customer products and expected declines for three new products in 2026.

Summary

• The filing is an amendment (Form 10-Q/A) to the original Quarterly Report on Form 10-Q for the period ended September 26, 2025, solely to add narrative context to the sales outlook in the Management's Discussion and Analysis section.
• No changes have been made to any of the financial information presented in the original Form 10-Q.
• Sales for the third quarter of 2025 increased by $36.3 million (8.4%) to $467.7 million compared to the same period in 2024, and by $114.5 million (9.0%) to $1,381.6 million for the first nine months of 2025.
• Income from continuing operations for Q3 2025 was $39.7 million ($1.11 per diluted share), up from $36.3 million ($1.01 per diluted share) in Q3 2024.
• Income from continuing operations for the first nine months of 2025 was $54.2 million ($1.52 per diluted share), down from $88.1 million ($2.49 per diluted share) in the same period of 2024, primarily due to a $46.7 million debt conversion inducement expense.
• The company completed two acquisitions in early 2025: Precision Coating LLC (January 7, 2025) and Vertical Solutions, Inc. d/b/a VSi Parylene (February 28, 2025), enhancing surface coating capabilities.
• The Portable Medical Exit, announced in 2022, is expected to be completed with final sales and market exit during the fourth quarter of 2025.
• Integer Holdings issued $1.0 billion in 1.875% Convertible Senior Notes due 2030 on March 18, 2025, using proceeds to fund capped call transactions, exchange $383.7 million of 2028 Convertible Notes, and pay down existing credit facilities.

Sentiment

Score: 4

Explanation: While Q3 2025 financial results show strong growth in sales and income from continuing operations, and the company demonstrates robust liquidity and debt management, the forward-looking sales outlook for specific new products in 2026 is negative due to lower-than-anticipated market adoption. The significant one-time debt conversion inducement expense also negatively impacted nine-month profitability. The amendment's primary purpose is to disclose this challenging sales outlook, indicating a cautious sentiment for future performance despite current strengths.

Positives

• Strong sales growth in Q3 2025 (8.4%) and the first nine months of 2025 (9.0%), driven by demand, new product ramps, emerging customers, and recent acquisitions.
• Gross profit increased by $9.6 million (8.2%) in Q3 2025 and $33.4 million (9.8%) in the first nine months of 2025, with gross margin remaining stable or slightly improving.
• Interest expense decreased by $5.2 million (35.7%) in Q3 2025 and $9.2 million (21.4%) in the first nine months of 2025, primarily due to lower weighted average interest rates from replacing variable-rate debt with lower fixed-rate convertible notes.
• Successful strategic acquisitions of Precision Coating and VSi Parylene have expanded service offerings and proprietary coating capabilities.
• The company maintains a strong liquidity position with $58.9 million in cash and cash equivalents, $568.3 million in working capital, and a current ratio of 3.71 as of September 26, 2025.
• Compliance with all financial covenants under its Senior Secured Credit Facilities, with a Total Net Leverage Ratio of approximately 2.6:1.0 and an Interest Coverage Ratio of approximately 11.2:1.0.
• The Portable Medical Exit is on track for completion in Q4 2025, allowing reallocation of manufacturing capacity to support growth.

Negatives

• Sales outlook for 2025 was updated to reflect lower than anticipated demand for select emerging customers' products.
• Sales of three new products (two electrophysiology, one neuromodulation) are expected to decline in 2026 due to lower than anticipated market adoption.
• Income from continuing operations and diluted EPS for the first nine months of 2025 decreased significantly (38.4% and 39.0% respectively) compared to 2024, largely due to a $46.7 million debt conversion inducement expense.
• Operating expenses increased by $11.2 million (19.1%) in Q3 2025 and $19.3 million (10.1%) in the first nine months of 2025, primarily due to higher SG&A expenses and restructuring/other charges.
• Other Markets sales decreased by 15.5% in Q3 2025 and 30.9% in the first nine months of 2025, driven by the Portable Medical Exit.

Risks

• Dependence upon a limited number of customers and pricing pressures from contractual restraints.
• Reliance on third-party suppliers for raw materials, key products, and subcomponents, leading to potential supply chain disruptions.
• Interruptions in manufacturing operations and uncertainty surrounding macroeconomic and geopolitical factors (e.g., inflation, interest rates, conflicts, tariffs).
• Ability to attract, train, and retain qualified associates to maintain and grow the business.
• Potential for harm to reputation and competitive advantage due to quality problems related to products.
• Dependence upon information technology systems and the ability to prevent cyber-attacks and other failures.
• Global climate change and the emphasis on Environmental, Social and Governance (ESG) matters by various stakeholders.
• Dependence upon the senior management team and key technical personnel.
• Consolidation in the healthcare industry resulting in greater competition.
• Ability to accurately forecast future performance based on often fluctuating operating results.
• Significant amount of outstanding indebtedness and the ability to remain in compliance with financial and other covenants.
• Economic and credit market uncertainties that could interrupt access to capital markets, borrowings, or financial transactions.
• Conditional conversion features of the 2028 and 2030 Convertible Notes, potentially impacting liquidity and diluting ownership interests.
• Counterparty risk associated with capped call transactions.
• Financial and market risks related to international sales and operations, including foreign currency exchange rate fluctuations.
• Complex international tax profile and the ability to realize the full value of intangible assets.
• Regulatory issues resulting from product complaints, recalls, or regulatory audits.
• Potential of becoming subject to product liability or intellectual property claims.
• Ability to protect intellectual property and proprietary rights.
• Ability to comply with customer-driven policies and third-party standards or certification requirements.
• Ability to obtain and/or retain necessary licenses from third parties for new technologies.
• Costs and ability to comply with environmental regulations.
• Legal and regulatory risks from international operations.
• The highly regulated nature of the healthcare industry and potential impact of cost containment measures.

Future Outlook

The company updated its sales outlook for 2025, reflecting lower than anticipated demand for select emerging customers' products. Sales of three new products (two electrophysiology and one neuromodulation) are expected to decline in 2026 due to lower than anticipated market adoption. The Portable Medical Exit is on track to be completed in the fourth quarter of 2025. Management believes projected cash flows from operations, available cash, and Revolving Credit Facility borrowings are sufficient to meet working capital, debt service, and capital expenditure requirements for the next twelve months.

Management Comments

• We recently updated our sales outlook for 2025, primarily to reflect lower than anticipated demand for select emerging customers products.
• Based on recent customer updates, we expect sales of three new products to decline in 2026, two electrophysiology products and one neuromodulation product from an emerging customer with PMA products.
• We believe the magnitude of these changes on multiple products at the same time is highly unusual.
• The market adoption of these products has been lower than anticipated.
• Based on current expectations, we believe that our projected cash flows provided by operations, available cash and cash equivalents and borrowings under our Revolving Credit Facility are sufficient to meet our working capital, debt service and capital expenditure requirements for the next twelve months.

Industry Context

Integer Holdings Corporation operates as one of the largest medical device contract development and manufacturing organizations (CDMO) globally. It serves critical markets including cardiac rhythm management, neuromodulation, and cardio and vascular. The industry is characterized by intense competition, rapid technological changes, and high regulatory scrutiny. The company's strategic acquisitions of Precision Coating and VSi Parylene reflect a trend towards expanding specialized service offerings to meet evolving customer needs in the medical device sector.

Stakeholder Impact

• Shareholders: Face potential dilution from the conditional conversion feature of the 2028 and 2030 Convertible Notes. The updated sales outlook for new products may impact future stock performance.
• Customers: Strong demand in Cardio & Vascular and new product ramps are positive, but lower than anticipated adoption for some emerging products indicates challenges. Customers in the Portable Medical market are being transitioned to other suppliers.
• Employees: Headcount increased due to recent acquisitions, but termination benefits were incurred from actions to align labor with manufacturing volumes.
• Creditors: The company is in strong compliance with debt covenants and has reduced its weighted average interest rate by replacing variable-rate debt with fixed-rate convertible notes, indicating a stable credit profile.

Next Steps

• Completion of the Portable Medical Exit during the fourth quarter of 2025.
• Continued evaluation of the potential impact of the EU's Pillar Two Framework on future tax periods.
• Continued evaluation of the One Big Beautiful Bill Act (OBBBA) for current-year financial reporting implications.
• Monitoring economic conditions and taking actions to align cost structure with changes in demand and manage working capital.

Key Dates

Recommendation

Integer Holdings demonstrates solid Q3 2025 financial performance with strong sales growth, stable gross margins, and effective debt management, including a significant reduction in interest expense and robust liquidity. Strategic acquisitions are also a positive. However, the explicit disclosure in this amendment regarding lower-than-anticipated market adoption for key new products and an expected sales decline in 2026 for these products introduces a notable forward-looking headwind. Additionally, the substantial one-time debt conversion inducement expense impacted nine-month profitability. Given the mixed signals of strong current operations versus a cautious future sales outlook for specific products, a 'hold' recommendation is appropriate. Investors should monitor the company's ability to address the new product adoption challenges and the impact on 2026 revenues.

Keywords

Medical device, Contract manufacturing, Cardiac rhythm management, Neuromodulation, Cardio and vascular, SEC filing, 10-Q/A, Financial results, Sales outlook, Acquisitions, Debt, Convertible notes, Medical technology, Precision Coating, VSi Parylene